join us before SynBioBeta for all things decentralized science next Monday w/ our friends Fifty Years Molecule Paul Kohlhaas bio/acc

A prescient reminder that pharma is almost always pro-cyclical when it comes to M&A. Not convinced that the vast wasteland of struggling publics will drive M&A (even firesale). Immense value destruction in the coming quarters.

Phenomenal contribution to the techbio canon by Amee Kapadia Pablo Lubroth and many others. A must read.

The American dream feeds on perpetual, exceptional optimism

Atoms, agents and transformers - AI x Bio summit 2023 is a wrap Huge shoutout to NYSE 🏛 for hosting us!

Only in Kendall Sq MBTA

Spring sunset over Kendall Square & Massachusetts Institute of Technology (MIT)

bio/acc 🧬

Learning to fail, fast and early in life, is an incredibly underrated superpower.

Can we connect pharma R&D to commercial teams (and vice versa) for smarter drug development? I'm excited to host the "Full Stack Pharma" roundtable with Chris Leiter at the AI x Bio Summit at NYSE 🏛.

What if computationally designed enzymes in the future are all multi-step? Eg - they have multiple active sites for different reactions? The new-ish David Baker paper on serine hydrolases has me thinking 🧬

Distibution. Distribution. Distribution. One of the biggest misses I see in early stage deeptech bio companies is a fundamental lack of awareness of distribution. Focusing on customer discovery, showing a deep understanding of needs and unique insights in the market is gold.

Wordle × Atria crossover I’ve been waiting for. 🟩⬜🟨🟨⬜ 🟩🟩🟩🟩🟩